| __timestamp | Merck & Co., Inc. | Sanofi |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 8565000000 |
| Thursday, January 1, 2015 | 10313000000 | 9496000000 |
| Friday, January 1, 2016 | 9762000000 | 9592000000 |
| Sunday, January 1, 2017 | 9830000000 | 10164000000 |
| Monday, January 1, 2018 | 10102000000 | 9934000000 |
| Tuesday, January 1, 2019 | 10615000000 | 9883000000 |
| Wednesday, January 1, 2020 | 8955000000 | 9390000000 |
| Friday, January 1, 2021 | 9634000000 | 9555000000 |
| Saturday, January 1, 2022 | 10042000000 | 10539000000 |
| Sunday, January 1, 2023 | 10504000000 | 10765000000 |
| Monday, January 1, 2024 | 9183000000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Merck & Co., Inc. and Sanofi have demonstrated contrasting strategies in this area. From 2014 to 2023, Merck's SG&A expenses fluctuated, peaking in 2014 and 2019, while Sanofi showed a more consistent upward trend, culminating in a 26% increase by 2023. Notably, in 2023, Sanofi's SG&A expenses surpassed Merck's by approximately 2.5%, highlighting a shift in spending dynamics. This data provides a fascinating insight into how these pharmaceutical giants allocate resources to support their operations and growth. As the industry evolves, understanding these financial strategies becomes essential for investors and stakeholders alike.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Sanofi or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited